Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Atara Biotherapeutics, Inc.

< Previous 1 2 3 4 Next >
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Names Biopharmaceutical Executive Charlene Banard as Chief Technical Officer
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Host EBV and MS Day
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Provides Update on ATA2271 Autologous CAR T Trial
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
New Landmark Nature Study Provides Long-Sought Mechanistic Link Between EBV and Multiple Sclerosis, Extending Findings from Recent Paper in Science That Identified EBV as the Leading Cause of Multiple Sclerosis
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Tickers ATRA
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.